13D Filing: Sarissa Capital Management and Novelion Therapeutics Inc. (NVLN)

This statement constitutes Amendment No. 2 to the Schedule 13D (this “Amendment No. 2”) relating to the Common Stock, without par value (the “Shares”), issued by Novelion Therapeutics, Inc. (the “Issuer”), and hereby amends the Schedule 13D filed with the Securities and Exchange Commission on December 5, 2016, as amended by Amendment No. 1 thereto filed with the Securities and Exchange Commission on June 30, 2017 (the “Initial Schedule 13D”), on behalf of the Reporting Persons (as defined in the Initial Schedule 13D), to furnish the additional information set forth herein.  All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Initial Schedule 13D.

Item 4. Purpose of Transaction.

Item 4 of the Initial Schedule 13D is hereby amended by adding the following:

On August 1, 2017, the Board of Directors of the Issuer appointed Mark DiPaolo to serve as a director.  Mr. DiPaolo is a partner and the General Counsel of Sarissa Capital.